These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32972785)

  • 1. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
    Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma.
    Pouwer AW; Te Grootenhuis NC; Hinten F; de Bock GH; van der Zee AGJ; Melchers WJG; Oonk MHM; de Hullu JA; Hollema H; Bulten J
    Virchows Arch; 2024 Jun; 484(6):985-994. PubMed ID: 37938322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
    Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
    Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
    Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
    J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
    Sznurkowski JJ; Żawrocki A; Biernat W
    BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers p16, Human Papillomavirus and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva.
    Hay CM; Lachance JA; Lucas FL; Smith KA; Jones MA
    J Low Genit Tract Dis; 2016 Jul; 20(3):252-6. PubMed ID: 26855143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.
    McAlpine JN; Leung SCY; Cheng A; Miller D; Talhouk A; Gilks CB; Karnezis AN
    Histopathology; 2017 Aug; 71(2):238-246. PubMed ID: 28257152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach.
    Yang H; Almadani N; Thompson EF; Tessier-Cloutier B; Chen J; Ho J; Senz J; McConechy MK; Chow C; Ta M; Cheng A; Karnezis A; Huvila J; McAlpine JN; Gilks B; Jamieson A; Hoang LN
    Mod Pathol; 2023 Jun; 36(6):100145. PubMed ID: 36828360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.
    Woelber L; Prieske K; Eulenburg C; Oliveira-Ferrer L; de Gregorio N; Klapdor R; Kalder M; Braicu I; Fuerst S; Klar M; Strauss HG; Beckmann M; Meier W; Ignatov A; Mustea A; Jueckstock J; Schmidt G; Bauerschlag D; Hellriegel M; Canzler U; Petry KU; Kommoss S; Hantschmann P; Heubner M; Mahner S; Burandt E
    Am J Obstet Gynecol; 2021 Jun; 224(6):595.e1-595.e11. PubMed ID: 33453182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Exome Sequencing of Vulvar Squamous Cell Carcinomas Reveals an Impaired Prognosis in Patients With TP53 Mutations and Concurrent CCND1 Gains.
    Ordi O; Saco A; Peñuelas N; Blanco-Irazuegui O; Pino MD; Carreras-Dieguez N; Marimon L; Rodrigo-Calvo MT; Morató A; Sisuashvili L; Bustamante M; Cruells A; Darecka K; Vega N; Alós S; Trias I; Fusté P; Parra G; Gut M; Munmany M; Torné A; Jares P; Rakislova N
    Mod Pathol; 2024 Oct; 37(10):100574. PubMed ID: 39089654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR).
    Dong F; Kojiro S; Borger DR; Growdon WB; Oliva E
    Am J Surg Pathol; 2015 Aug; 39(8):1045-53. PubMed ID: 26171917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
    Höhn AK; Forberger M; Alfaraidi M; Gilks CB; Brambs CE; Höckel M; Hoang L; Singh N; Horn LC
    Gynecol Oncol; 2024 Jun; 185():17-24. PubMed ID: 38342005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus (HPV) and HPV 16-variant distribution in vulvar squamous cell carcinoma in Sweden.
    Larsson GL; Helenius G; Andersson S; Elgh F; Sorbe B; Karlsson MG
    Int J Gynecol Cancer; 2012 Oct; 22(8):1413-9. PubMed ID: 23013732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features.
    Carreras-Dieguez N; Saco A; Del Pino M; Marimon L; López Del Campo R; Manzotti C; Fusté P; Pumarola C; Torné A; Garcia A; Rakislova N
    Histopathology; 2023 Jul; 83(1):17-30. PubMed ID: 37099408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors.
    Allo G; Yap ML; Cuartero J; Milosevic M; Ferguson S; Mackay H; Kamel-Reid S; Weinreb I; Ghazarian D; Pintilie M; Clarke BA
    Int J Gynecol Pathol; 2020 Jul; 39(4):391-399. PubMed ID: 31274700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases.
    Cheng AS; Karnezis AN; Jordan S; Singh N; McAlpine JN; Gilks CB
    Int J Gynecol Pathol; 2016 Jul; 35(4):385-93. PubMed ID: 26630231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
    Sand FL; Nielsen DMB; Frederiksen MH; Rasmussen CL; Kjaer SK
    Gynecol Oncol; 2019 Jan; 152(1):208-217. PubMed ID: 30415992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV status and favourable outcome in vulvar squamous cancer.
    Wakeham K; Kavanagh K; Cuschieri K; Millan D; Pollock KG; Bell S; Burton K; Reed NS; Graham SV
    Int J Cancer; 2017 Mar; 140(5):1134-1146. PubMed ID: 27864932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.